Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen Corporation (NASDAQ:RGEN) will announce its Q4 and full-year 2022 financial results on February 22, 2023. A press release will precede the market opening, followed by a conference call at 8:30 a.m. EST. This event will discuss updates and financial results for the periods ended December 31, 2022. Investors can access the conference call by dialing (844) 274-3999 domestically or (412) 317-5607 internationally. The event will be archived for later access. Repligen focuses on bioprocessing technologies and operates globally, with key manufacturing sites in the U.S. and Europe.
Repligen Corporation (NASDAQ:RGEN) announced its participation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. CEO Tony J. Hunt will present on January 10 at 2:15 p.m. PST. The presentation will be available via a live webcast through the Company’s Investor Relations section and can be replayed afterwards for a limited time.
Repligen is a leader in bioprocessing technologies, focusing on improving efficiencies in manufacturing biological drugs and serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ:RGEN) announced its participation in two prominent investor conferences. The Stifel 2022 Healthcare Conference will take place on November 15-16 in New York, where CFO Jon K. Snodgres will lead a discussion on November 16 at 2:25 p.m. EST. Additionally, the Stephens’ Annual Investment Conference is set for November 15-17 in Nashville, with Snodgres speaking on November 17 at 2:00 p.m. EST. A live webcast will be available on the company’s website and can be replayed for a limited time after the events.
Repligen Corporation (RGEN) reported Q3 2022 revenue of $200.7 million, a 13% year-over-year increase. At constant currency, growth was 19%, with organic growth at 16%. The base business saw a solid 29% revenue growth, expected to reach 33%-34% for the full year. A significant 15-year agreement was established with DRS Daylight Solutions for real-time monitoring technology. Adjusted EPS decreased slightly to $0.77. The company maintains a positive outlook, anticipating overall revenue growth of 19%-20% as reported for 2022.
Repligen Corporation (NASDAQ:RGEN) has renewed its exclusive supply agreement with Purolite to develop affinity ligands for monoclonal antibodies, extending the partnership to 2032. This agreement allows Purolite to access new mAb fragment ligands developed at Avitide and strengthens Repligen's role in the supply of Protein A ligands. The collaboration aligns with Repligen's strategy to enhance market adoption of its Praesto® affinity resin portfolio and secure supply of agarose-based Protein A resins, further establishing their leadership in bioprocessing technologies.
Repligen Corporation (NASDAQ:RGEN) will report its Q3 2022 financial results on November 1, 2022. A press release will be issued before market opening, followed by a conference call at 8:30 a.m. EDT to discuss updates and results for the three and nine month periods ending September 30, 2022.
The call is accessible at (844) 274-3999 (domestic) or (412) 317-5607 (international). A webcast will also be available on the investor relations section of Repligen's website.
Repligen Corporation (NASDAQ:RGEN) has announced a strategic collaboration and exclusive license agreement with DRS Daylight Solutions, lasting 15 years. This partnership aims to enhance the use of mid-infrared (mid-IR) technology in bioprocessing. Repligen will commercialize Daylight's Culpeo® and develop additional products focused on Quantum Cascade Laser mid-IR solutions. This will facilitate real-time monitoring of critical biological manufacturing processes, improving production yields and ensuring product quality.
Repligen Corporation (NASDAQ:RGEN) has announced its upcoming Investor Day 2022 on September 20 in New York City, scheduled from 8:20 to 11:30 a.m. EDT. This live event will feature presentations from the leadership team, followed by a Q&A session. Attendees can register for the in-person event, which is limited to institutional investors and analysts, or access the live webcast on the company's Investor Relations website. A replay will be available post-event.
Repligen Corporation (RGEN) reported record revenue of $207.6 million for Q2 2022, marking a 27% increase year-over-year, with 29% organic growth. The company raised its revenue guidance for the full year 2022 to a range of $790 million to $810 million, up from the previous $770 million to $800 million. Q2 GAAP gross margin was 58.5%, and diluted EPS rose to $0.88, compared to $0.64 in Q2 2021. The strong performance was driven by significant growth in the base business, particularly in Filtration and Chromatography segments.
Repligen Corporation (NASDAQ:RGEN) will report its second quarter 2022 financial results on August 2, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss business updates and financial results for the period ending June 30, 2022. Investors can access the call via toll-free numbers for domestic and international callers and will also be available as a webcast on the company's website. The event will be archived for later access.